Fluidigm Completes Acquisition of InstruNor AS
Summary
Acquisition to expand Fluidigm’s industry-leading mass cytometry capabilities and address flow cytometry markets with the addition of fully automated sample prep SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it has completed the acquisition of InstruNor AS, the privately held provider of the only fully integrated sample preparation system for flow and mass cytometry. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding market sizes and growth rates, prospects for cytometry products, including market opportunities for Fluidigm products, an expectation, including timing, for an acquisition to become accretive to earnings, and anticipated product launches. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide.
Classifications
AskAI Classifications
LabelsLinked Companies
